Mereo BioPharma Group PLC ADR MREO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $0.32
- Day Range
- $0.31–0.34
- 52-Week Range
- $0.20–2.37
- Bid/Ask
- $0.34 / $0.34
- Shares Outstanding
- 159.62M
- Market Cap
- $53.47M
- Volume/Avg
- 1M / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 107.25
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 39
- Website
- https://www.mereobiopharma.com
Valuation
|
Metric
|
MREO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.57 |
Price/Sales | 107.25 |
Price/Cash Flow | — |
Price/Earnings
MREO
Financial Strength
|
Metric
|
MREO
|
|---|---|
Quick Ratio | 6.17 |
Current Ratio | 6.48 |
Interest Coverage | −394.27 |
Quick Ratio
MREO
Profitability
|
Metric
|
MREO
|
|---|---|
Return on Assets (Normalized) | −50.24% |
Return on Equity (Normalized) | −57.75% |
Return on Invested Capital (Normalized) | −60.95% |
Return on Assets
MREO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<&QB!W | LOCK|@hsF | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Sn!Pyz& | LOCK|#lWV | $70B | |||
| argenx SE ADR
ARGX
| LOCK|%&?#DT | LOCK|#^j | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|!x#>lP | LOCK|dQsB$ | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Td^cY#^ | LOCK|P!K | $36B | |||
| Moderna Inc
MRNA
| LOCK|%?D$^w& | LOCK|wz | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|<&V!>j<J | LOCK|M$hP? | $25B | |||
| Incyte Corp
INCY
| LOCK|><b#^X | LOCK|pk | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|?#j?Z&C | LOCK|%P | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|l&DD^^P | LOCK|^<b | $17B |
United States